-
1 week ago | 
dermatologytimes.com | Emma Andrus
JEADV Clinical Practice: Exploring the Cutaneous Associations of Crohn's Disease: A Retrospective Study of 108 PatientsA recent retrospective chart review examined dermatologic associations in patients with Crohn disease seen at Wake Forest Baptist Dermatology between 2010 and 2024. Researchers analyzed 108 patient records, with statistical comparisons made using χ² and 2-tailed t-tests. The majority of patients were female (54.6%) and White (80.6%).
-
1 week ago | 
dermatologytimes.com | Emma Andrus
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Facial hyperpigmentation may signal systemic disease. Dermatologists must assess beyond melasma to ensure timely, accurate diagnosis and care. In a large study, nearly half of SIND patients also had other BFRBs like skin picking or hair pulling. Evommune has initiated a global phase 2b trial of EVO756, a first-in-class MRGPRX2 antagonist, for moderate to severe CSU.
-
1 week ago | 
dermatologytimes.com | Emma Andrus
Evommune, Inc.
-
1 week ago | 
dermatologytimes.com | Emma Andrus
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Experts explore how rosacea research is evolving, with new treatments, gaps in care, and a push for more inclusive, targeted approaches. Untreated or undertreated AD can lead to poor sleep, infections, and stunted development. The novel formulation was compared to a petrolatum-based diaper and was found to be just as effective for irritation and redness.
-
1 week ago | 
dermatologytimes.com | Emma Andrus
New interim data from an ongoing investigator-initiated study demonstrates the potential of Soligenix, Inc.'s HyBryte (synthetic hypericin), formerly SGX301, as a promising treatment option for early-stage cutaneous T-cell lymphoma (CTCL).1Soligenix released these latest findings, which showed strong early efficacy and safety results, that reaffirm prior phase 3 trial outcomes.
-
1 week ago | 
dermatologytimes.com | Emma Andrus
Welcome to Dermatology Times' Sunday Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.
-
1 week ago | 
dermatologytimes.com | Emma Andrus
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Menopausal acne is rising yet underexplored; treatment must address hormonal shifts, skin sensitivity, and patient emotional well-being. The company also announced in a press release that the product received the Seal of Acceptance by the NEA. Subcutaneous methotrexate may offer improved efficacy and patient adherence in psoriasis treatment, though it comes at a higher cost.
-
1 week ago | 
dermatologytimes.com | Emma Andrus
A recent literature review examined the effectiveness of subcutaneous methotrexate in patients with plaque psoriasis.1The review, published in the International Journal of Dermatology, reported greater efficacy in cases of subcutaneous administration versus oral therapy. While methotrexate has long been used in psoriatic disease due to its efficacy and cost-effectiveness,2 the choice between oral and subcutaneous administration routes has remained an area of ongoing clinical discussion.
-
2 weeks ago | 
dermatologytimes.com | Emma Andrus
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters. Bill Damsky, MD, PhD, pioneers molecular diagnostics to close the gap between research and clinical care in inflammatory skin disease. A new subgroup analysis revealed higher rates of clear or almost clear skin at week 16 vs placebo with a favorable safety profile.
-
2 weeks ago | 
dermatologytimes.com | Emma Andrus
The International League of Dermatological Societies (ILDS) recently shared details of 2 organizational developments: the renewal of its Official Relations status with the World Health Organization (WHO),1 and the release of an official position statement addressing the growing misuse of topical corticosteroids in skin-bleaching products.2Dermatology Times recently spoke with Henry W.
